June 22, 2019: Dr. Cheni Kwok will be moderating a featured panel discussion titled
"Innovative therapy in oncology, what is next?"
at the
2019 Biopacific Conference (21st Annual Conference of CABS).
April 1, 2019: Linear Dreams is retained by Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
to support its business development efforts. The company will be representing Rigel Pharmaceuticals
at the BIO International Convention 2019 in Philadephia on June 3-6, 2019.
November 27, 2018: Shanghai Henlius Biotech announced two new alliances with Biosidus
S.A. and Cipla Ltd.. Linear Dreams represented Shanghai Henlius to initiate, structure and negotiate
both partnerships. Biosidus S.A. is granted an exclusive license to develop and commercialize
HLX01, a proprietary rituximab biosimilar of Shanghai Henlius in certain countries in Latin America.
Cipla Ltd. shall have the exclusive rights to develop and commercialize HLX02, a proprietary trastuzumab
biosimilar of Shanghai Henlius, in certain countries in Asia Pacific and Latin America. Shanghai Henlius
shall be the commercial manufacturer and supplier of HLX01 and HLX02 for Biosidus and Cipla respectively.
A New Drug Application for HLX01 is currently under review by the National Medical Products Administration
of China. HLX02 is currently in a global, multi-center, double-blind, randomized Phase III trial.
November 1, 2018: Represented Shanghai Henlius Biotech to expand the exclusive rights
to develop and commercialize AC101 (now HLX 22) licensed from AbClon, Inc. from Greater China to
worldwide. The IND application of HLX22 has been accepted by the National Medical Products
Administration of China on November 26, 2018.
June 21, 2018: Represented Shanghai Henlius Biotech to initiate, structure and negotiate
an exclusive license agreement with Accord Healthcare to develop and market HLX02, a
proprietary trastuzumab biosimilar product of Shanghai Henlius in 53 countries from Europe,
17 countries in Middle East and North Africa (MENA) region and certain countries in Commonwealth of
Independent States (CIS). Shanghai Henlius shall be the commercial manufacturer and supplier of HLX02 for Accord.
HLX02 is currently in a global, multi-center, double-blind, randomized Phase III trial.
February 14, 2018: Represented Shanghai Henlius Biotech to structure and negotiate an
exclusive license agreement with Galaxy Biotech, LLC., in USA for the development and
commercialization rights of novel monoclonal antibodies targeting the Death Receptor
pathway (“Products”) in Greater China, including an option to expand to worldwide rights.
The Products have first-in-class potential and target a broad range of solid and hematologic tumors.
December 20, 2017: Represented Shanghai Henlius Biotech to structure, negotiate and
execute a licensing framework agreement whereby Jacobson Medical will be granted an
exclusive right to develop and market HLX02, a proprietary trastuzumab biosimilar product
of Shanghai Henlius in Hong Kong and Macau, and a right of first negotiation for certain
emerging markets within the Association of Southeast Asian Nations (ASEAN). HLX02 is
currently in a global, multi-center, double-blind, randomized Phase III study.
April 6, 2017: Represented Immune-Onc Therapeutics Inc. to establish a worldwide exclusive
license and collaboration agreement with The University of Texas Health Science Center at Houston
and The University of Texas Southwestern Medical Center.
March 28, 2017: Represented Immune-Onc Therapeutics Inc. to structure and negotiate an
exclusive worldwide license agreement with Albert Einstein College of Medicine and Memorial Sloan
Kettering Cancer Center.
November 2, 2016: Represented Shanghai Henlius Biotech to initiate, structure and
negotiate an exclusive license agreement with Kolltan Pharmaceuticals, Inc., in USA for the
development and commercialization rights of KTN0216 in Greater China and 15 countries in Asia
Pacific region. KTN0216 is a novel antibody targeting c-MET discovered by Kolltan in preclinical
development.
October 29, 2016: Represented Shanghai Henlius Biotech to structure and negotiate an exclusive
license agreement with AbClon Inc., based in Korea for the development and commercialization rights
of AC101 in Greater China, including an option to expand to worldwide rights. AC101 is an innovative
antibody developed by AbClon targeting gastric cancer and breast cancer in preclinical development.
August 16, 2016: Represented Shanghai Henlius Biotech in the negotiation of an exclusive
license agreement with Shanghai Jing Ze Biotech for the development and commercialization rights of
HLX-05 in China. HLX-05, a cetuximab biosimilar developed by Shanghai Henlius Biotech, received IND
approval for two indications by the China FDA.
May 14, 2016: Linear Dreams supports GF Xinde to close a Life Sciences Fund with Bay City Capital.